Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

4688 - BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population


10 Sep 2017


Breast cancer, metastatic


Clinical Research;  Breast Cancer


Nicholas  Turner


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


N. Turner1, E. Alarcón2, A. Armstrong3, M. Philco4, Y.A. López Chuken5, M. Sablin6, K. Tamura7, A. Gomez Villanueva8, J.A. Pérez-Fidalgo9, A. Foxley10, J. Lindemann10, R. Maudsley10, E. Outhwaite10, M. Pass10, P. Rugman10, G. Schiavon10, M. Oliveira11

Author affiliations

  • 1 Molecular Oncology, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Clinical Oncology, Clínica Anglo Americana, Lima/PE
  • 3 Faculty Of Biology, Medicine And Health, The Christie NHS Foundation Trust and the University of Manchester, Manchester/GB
  • 4 Clinical Oncology, Instituto Peruano de Oncología & Radioterapia, Lima/PE
  • 5 Clinical Oncology, Hospital Universitario, Monterrey/MX
  • 6 Medical Oncology, Curie Institute, Paris/FR
  • 7 Breast And Medical Oncology, National Cancer Center Hospital, Tokyo/JP
  • 8 Oncology & Hematology, Centro Hemato-Oncológico Privado, Toluca/MX
  • 9 Oncology, INCLIVA Research Institute and Hospital Clínico Universitario de Valencia, Valencia, CIBERONC/ES
  • 10 Early Clinical Development, AstraZeneca, Cambridge/GB
  • 11 Medical Oncology, Vall d’Hebron University Hospital, Barcelona/ES


Abstract 4688


AZD5363 (AZD) potently and selectively inhibits AKT1–3. PIK3CA mutations increase sensitivity to AZD in vitro and in vivo. We conducted a randomised Phase 2 trial (NCT01625286), to compare the efficacy of AZD versus placebo, in combination with weekly paclitaxel, in advanced or metastatic ER+ve/HER2−ve breast cancer, and in a PIK3CA mutation sub-population (PIK3CA+).


Female patients (N = 110) aged ≥18 years with ER+ve/HER2−ve advanced or metastatic breast cancer who had received no prior chemotherapy in the advanced or metastatic setting were enrolled. Patients were randomised 1:1, stratified by PIK3CA mutation status (PIK3CA+ vs PIK3CA− in tissue or circulating tumour DNA), to receive paclitaxel 90 mg/m2 i.v. once weekly for 3 weeks out of 4, plus oral AZD 400 mg, or matched placebo twice daily 4 days on, 3 days off, starting on the day after each paclitaxel administration. Enrolment was capped to ensure 50 PIK3CA+ patients were enrolled. Progression status and tumor response (RECIST 1.1) was assessed every 12 weeks. The primary endpoint was investigator-assessed progression-free survival (PFS).


Median PFS was 10.9 months (95% CI 8.3–12.4) on AZD plus paclitaxel versus 8.4 months (95% CI 8.2–10.8) on placebo plus paclitaxel (HR 0.80, 80% CI 0.6–1.06, p = 0.31). In the PIK3CA+ subgroup, median PFS was 10.9 months (95% CI 8.7–11.5) on AZD plus paclitaxel versus 10.8 months (95% CI 8.3–14.3) on placebo plus paclitaxel (HR 1.11, 80% CI 0.73–1.68, p = 0.76). Objective response rate was 59% on AZD plus paclitaxel versus 57% on placebo plus paclitaxel. The most common adverse events were diarrhoea (76% AZD vs 27% placebo), alopecia (52% vs 49%), nausea (39% vs 24%) and anaemia (33% vs 27%). Adverse events grade 3 or higher included diarrhoea (24% vs 2%), hyperglycaemia (13% vs 0%) and neutropenia (11% vs 9%). Discontinuation rates due to adverse events were 13% on AZD and 7% on placebo.


Adding AZD to weekly paclitaxel did not prolong PFS in the overall population or PIK3CA+ subgroup of ER+ve/HER2−ve advanced or metastatic breast cancer.

Clinical trial identification

ClinicalTrials.gov NCT01625286 Other Study ID Numbers: D3610C00002; 2011-006312-31 (EudraCT Number)

Legal entity responsible for the study

AstraZeneca (Study Director: Justin PO Lindemann)




N. Turner: Advisory board honoraria and research funding from AstraZeneca. A. Armstrong: Fees from Roche and Syndax for consulting/advisory roles. M-P. Sablin: Within the last year, travel/accommodation expenses paid/reimbursed by Pfizer. K. Tamura: As the responsible project lead (e.g., Principal Investigator), Direct research support from AstraZeneca, Daiichi Sankyo, MSD and Pfizer. A. Gomez Villanueva: Research funding from AstraZeneca, PPD, Quintiles. J.A. Pérez-Fidalgo: Fees from AstraZeneca, Ipsen, Novartis, Pfizer and Roche for participation in speaker bureaus. Travel/accommodation expenses paid/reimbursed by AstraZeneca, Roche and Sandoz. A. Foxley, J. Lindemann, R. Maudsley, P. Rugman: Employee at AstraZeneca (and shareholder). E. Outhwaite: Employee of AstraZeneca via freelance contract with Aptus Clinical. M. Pass: Employee at AstraZeneca (and shareholder with intellectual property interests). G. Schiavon: Employee at AstraZeneca. M. Oliveira: Fees from Genentech/Roche and PUMA Biotechnology for consulting/advisory roles. Research funding to the institution from AstraZeneca and Genentech/Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.